ALLMedicine™ Myeloproliferative Disease Center

Dec 16th, 2021 - Stem Cell leukemia/lymphoma syndrome (SCLL) presents as a myeloproliferative disease which can progress to acute myeloid leukemia and is associated with the coincident development of B-cell and T-cell lymphomas. SCLL is driven by the constitutive ...

Dec 10th, 2021 - This case study describes the presentation of a 76-year-old male with a past medical history that included atrial fibrillation, essential hypertension, coronary artery disease status post cardiac stent placement, heart failure, hyperlipidemia, thy...

Dec 3rd, 2021 - Not available.

Sep 22nd, 2021 - BACKGROUND Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension which is often caused by recurrent emboli. The reported prevalence in Latvia is 15.7 cases per million inhabitants. Several risk factors pred...

Aug 25th, 2021 - Discovery of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the therapy of chronic myeloid leukemia (CML), a malignant myeloproliferative disease characterized by abnormal activation of BCR-ABL fusion oncoprotein with protein tyrosi...

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

Aug 23rd, 2021 - PRIMARY OBJECTIVE: I. Determine the tolerability of the addition of standard dose salsalate to the standard treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine [5-azacytidine]). SECONDARY OBJECTIVES: I. Det...

Aug 6th, 2021 - Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal, superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in the general population based on autopsy reports. However, 40-50% o...

Aug 3rd, 2021 - Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative disease with an incidence of one to two cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. The introduction of imatinib,...

Aug 13th, 2019 - Study type An observational study conducted in different hematological centers in Belgium. Study objectives Primary objective: To assess the impact of newly started treatments on the QOL of patients suffering from myelodysplastic syndromes. Second...

Nov 26th, 2014 - Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic anemia (low red blood c...

Apr 2nd, 2021 - Transcript: Richard F. Schlenk, MD: Acute myeloid leukemia [AML] is a hematological disease focused on myeloid cells. It’s characterized by different mutations, which occur in the hematopoietic stem cells but also the hematopoietic progenitor ...

Dec 20th, 2020 - Ellen K. Ritchie, MD Investigators are in the midst of exploring novel therapeutic regimens for patients with myeloproliferative neoplasms (MPNs), as well as working to obtain a deeper understanding of the biology of these rare conditions. With ...

Dec 20th, 2020 - James M. Rossetti, DO When it comes to the treatment of patients with myeloproliferative neoplasms (MPNs), assessing for potential disease-related symptoms is key, said James M. Rossetti, DO. Moreover, risk stratification in all of the diseases a...

Dec 5th, 2020 - Elaine R. Mardis, PhD, discusses genomic insights into resistance mechanisms in endocrine therapy. Although breast cancer is among the best-characterized tumor types, continuing efforts to refine the sequencing of the human genome are opening th...

Jul 15th, 2016 - Cord blood donation Photo courtesy of NHS Researchers have discovered a genetic switch that could increase the supply of hematopoietic stem cells (HSCs) derived from cord blood, according to a paper published in Cell Stem Cell. However, experiment.